ITPに対するTPO受容体作動薬治療中に発症した慢性骨髄性白血病

DOI Web Site PubMed

書誌事項

タイトル別名
  • Development of chronic myelogenous leukemia during treatment with TPO receptor agonist for ITP
  • ITP ニ タイスル TPO ジュヨウタイ サドウヤク チリョウ チュウ ニ ハッショウ シタ マンセイ コツズイセイ ハッケツビョウ

この論文をさがす

抄録

We report a 77-year-old Japanese man with idiopathic thrombocytopenic purpura (ITP) which developed into chronic myelogenous leukemia (CML) during treatment with eltrombopag, a thrombopoetin (TPO) receptor agonist, because the disease was refractory to prednisolone. Eltrombopag can induce a good reaction in terms of the platelet count. However, CML in the chronic phase developed in about 19 months in our present case. Dasatinib was administered because he had diabetes. However, a blastic crisis immediately occurred. He died despite switching to Nilotinib. Recently, the occurrence of myelofibrosis and hematological malignancies due to long-term use of TPO receptor agonists has become a concern. This is the first report of a TPO receptor agonist possibly contributing to CML onset and crisis.

収録刊行物

  • 臨床血液

    臨床血液 55 (12), 2429-2432, 2014

    一般社団法人 日本血液学会

キーワード

詳細情報 詳細情報について

問題の指摘

ページトップへ